Revenue segments as reported by the company.

Technology & Analytics Solutions

Research & Development Solutions

Contract Sales & Medical Solutions

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Depreciation and amortization

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IQVIA Hlds

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IQVIA reports solid Q4 performance, addresses macro challenges proactively

IQVIA delivered a strong performance in Q4 2022 with revenue growth, operational achievements, and solid financial guidance for 2023, underlining its market position and strategic focus.
While facing challenges from macroeconomic factors, wage inflation, and market conditions, the company is proactively addressing these issues through cost-cutting measures and debt reduction strategies.
By leveraging its strengths in stable operations, record bookings, and financial discipline, IQVIA aims to navigate challenges, capitalize on opportunities, and drive sustainable growth in the future.

IQVIA reports solid Q1 growth amidst industry challenges and opportunities

IQVIA Hlds (IQV) Q1 2023 reflects strong financial performance and operational resilience.
Challenges in backlog burn and industry dynamics are being managed effectively.
Opportunities in M&A activity and demand for real-world evidence drive growth.
Steady guidance for 2023 positions the company well for future success.

IQVIA posts strong Q2 results, eyes growth amid AI investments

IQVIA's Q2 performance reflects solid growth and strategic wins in data and analytics solutions.
While facing challenges in decision delays and economic uncertainties, the company's AI investments and strong R&DS segment offer growth opportunities.
With a focus on leveraging AI across business areas and a vast patient data advantage, IQVIA is well-positioned for future success.

IQVIA reports mixed Q3 results, eyes growth through strategic initiatives

IQVIA's Q3 2023 performance showcased strength in R&DS bookings and revenue growth, while TAS faced challenges from foreign exchange and weak demand. The company aims to drive growth through new contracts, cost reduction initiatives, and strategic pricing adjustments, with a focus on stabilizing performance and pursuing growth opportunities in 2024.

IQVIA reports robust Q4 earnings, eyes growth amid challenges

IQVIA's strong performance in bookings and revenue growth positions it well for future success.
While facing challenges in TAS and pricing negotiations, IQVIA's contract wins and guidance for 2024 show resilience.
Opportunities lie in improving demand for TAS, increasing RFPs, and growth in the data business.
Overall, IQVIA's strategic wins and financial outlook indicate a positive trajectory for the company.

IQVIA reports solid Q1 performance, eyes growth through partnerships

IQVIA delivered a solid performance in Q1 2024, meeting revenue expectations and showcasing growth in bookings and pipeline. The company's strengths lie in technology-enabled solutions, global partnerships, and public health initiatives.
Challenges include cancellations impacting revenue, pricing pressures, and the need to navigate market dynamics. However, IQVIA's opportunities in innovation, partnerships, and market expansion position it well for future growth.
Overall, IQVIA's strategic focus on technology, client engagements, and public health initiatives, amidst challenges in cancellations and pricing pressures, presents a resilient outlook. The company's financial performance and industry leadership are key strengths.
With a proactive approach to challenges and a focus on seizing opportunities, IQVIA remains well-positioned for sustained growth and success in the evolving healthcare landscape. The company's adaptability and strategic initiatives drive confidence in its future prospects.

IQVIA reports robust Q2 earnings, eyes growth amidst market challenges

IQVIA Hlds delivered a strong Q2 performance with revenue and earnings growth, supported by efficient operations and solid financial metrics.
While facing challenges such as pricing pressures and market dynamics, the company remains optimistic about future opportunities and growth potential.
Strategic focus on addressing challenges and seizing opportunities will be key to sustaining performance and maximizing shareholder value in the dynamic healthcare landscape.

IQVIA Hlds reports Q3 growth, faces study delays and pricing challenges

IQVIA Hlds demonstrated solid financial performance in Q3 2024, driven by revenue growth and increased EPS.
While facing challenges like study delays and pricing pressures, the company's strategic strengths and opportunities for growth remain intact.
With a focus on share buybacks and R&DS growth, IQVIA is positioning itself for sustained success in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been recognized along with the National Basketball Association and partners at Harvard, Columbia and BioReference Laboratories for its work in supporting the league with the 2020 NBA Bubble. The Bubble was a closed-campus occupational health program implemented to ensure t.

IQVIA and the NBA Selected for Abbott's UNIVANTS of Healthcare Excellence Award

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, was recognized as the highest scoring provider in the ‘Leader' category of Everest Group's Life Sciences Sales and Marketing Operations PEAK Assessment. This assessment included 17 providers and measured them according to two metrics: the ability to have an impact on the market overall, and the extent to which their vision and c.

IQVIA selected ‘Leader' in Everest Group Life Sciences Sales and Marketing Operations PEAK Matrix® Assessment 2023

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been selected as winner of the “Best AI-based Solution for Healthcare” award in the sixth annual AI Breakthrough Awards, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) marke.

IQVIA Wins Prestigious “Best AI-based Solution for Healthcare” Award in 2023 Artificial Intelligence Breakthrough Awards

INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announced the launch of IQVIA RIM Smart Labeling, a comprehensive labeling solution for the life sciences industry that provides an intelligence-driven approach for more efficient and compliant global label management. Through this unique solution, life sciences companies can consolidate regulatory label planning, tracking and execution systems and workflows into one streamlined process. RIM Smart Labeling is part of IQVIA's suite.

IQVIA Launches RIM Smart Labeling to Deliver Intelligence-Driven Approach for Global Label Management

Microsoft

NVIDIA

Famed investor, Stanley Druckenmiller hasn't been shy about how bearish he is on the market, stating that he still believes there will be a hard landing sometime in the next year. However, he notes that “AI could be as transformative as the internet,” and that AI companies could have very strong earnings even in the face of an economic downturn.

Stanley Druckenmiller is Bullish on AI, these are His Top 3 Stock Picks

IQVIA Holdings' (IQV) enormous treasure trove of information is a distinguishing asset and also perhaps a big barrier to entry for competitors.

Why You Should Retain IQVIA Holdings (IQV) Stock for Now

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthening and save lives. The $5 million impact partnership will channel life-saving money.

IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening

ACADIA Pharma

Agios Pharmaceuticals

Amgen

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

BioMarin Pharmaceutical

CareDx

Exact Sciences

Exelixis

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Ionis Pharma

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Regeneron Pharmaceuticals

Seagen

Teladoc

TG Therapeutics

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

A strong database of patient records and a huge market are tailwinds for IQVIA's (IQV) success.

IQVIA's (IQV) Extensive Database Blocks New Entrants

Despite some concerns about TAS performance, overall demand remains robust. While TAS performance was weak in the first quarter, it is expected to recover in the second half of the year.

IQVIA Holdings: A Possible Beat And Raise Scenario In The Works

INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 (the “Senior Secured Notes”) and $500,000,000 in aggregate principal amount of senior notes due 2030 (the “Senior Notes” and, together wi.

IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes

INNOVATION PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the “Notes”). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering. The consummation of the Not.

IQVIA Announces Offering of Senior Secured Notes and Senior Notes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA). Sheetal earned the award for her strong and innovative leadership, combined with her exemplary work in IQVIA's clinical development business. Sheetal has consistently been at the forefront of critical industry initiatives, such as reducing the burden for p.

IQVIA Celebrates Sheetal Telang, Winner of Healthcare Businesswoman's Association Rising Star Award

Crown Castle International

ConocoPhillips

Copart

Cintas Corp

EPAM Systems

Generac Holdings

New Linde PLC

O'Reilly Automotive

Republic Services

Synopsys

Synchrony Financial

Take-Two Interactive Software

Thinking about selling in May and staying away from the S&P 500? Not so fast.

13 Stocks Pay You Very Well To Stay Invested In May

IQVIA Holdings (IQV) first-quarter 2023 revenues improve year over year.

IQVIA Holdings (IQV) Surpasses Q1 Earnings & Revenue Estimates

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2023. First-Quarter 2023 Operating Results Revenue for the first quarter of $3,652 million increased 2.4 percent on a reported basis and 4.7 percent at constant currency, compared to the first quarter of 2022. Te.

IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement (OCE) platform.

IQVIA Named a Leader in Everest Group Life Sciences Customer Experience Platforms PEAK Matrix® Assessment 2023

Market size and data reserve are positives for IQVIA Holdings (IQV). Foreign currency risk is bothersome.

Here's Why Investors Should Retain IQVIA Holdings (IQV) Stock

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

IQVIA to Announce First-Quarter 2023 Results on April 27, 2023

Southwest Airlines

Merck

Newell Brands

ON Semiconductor

Walgreens

Subscribers to  Chart of the Week  received this commentary on Sunday, April 2.

50 Second Quarter Stocks to Watch

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day.

IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization's focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.

IQVIA Publishes its 2022 Environmental, Social and Governance Report

Cigna

Danaher

All three companies have shown consistent revenue and EPS growth.

Got $300? 3 Growth Stocks to Buy That Could Double Your Money

IQVIA (IQV) fourth-quarter 2022 earnings and revenues surged year over year.

IQVIA (IQV) Q4 Earnings and Revenues Beat Mark, Rise Y/Y

IQVIA Holdings (NYSE:IQV ) Q4 2022 Earnings Conference Call February 10, 2023 9:00 AM ET Company Participants Nick Childs - Senior Vice President, Investor Relations and Treasurer Ari Bousbib - Chairman and Chief Executive Officer Ron Bruehlman - Executive Vice President and Chief Financial Officer Eric Sherbet - Executive Vice President and General Counsel Mike Fedock - Senior Vice President, Financial Planning and Analysis Gustavo Perrone - Senior Director, Investor Relations Conference Call Participants Dan Leonard - Credit Suisse Eric Coldwell - Robert W. Baird Justin Bowers - Deutsche Bank Jack Meehan - Nephron Luke Sergott - Barclays Sandy Draper - Guggenheim Elizabeth Anderson - Evercore ISI Charles Rhyee - Cowen Operator Ladies and gentlemen, thank you for standing by.

News for IQVIA Hlds Stock (IQV)